Effect of Rosuvastatin on Sever Preeclampsia Induced Inflammatory Response

Preeclampsia is a multisystem disorder that complicates 3-5% of pregnancies and remains a major cause of maternal, fetal, and neonatal morbidity and mortality.(1)

Preeclampsia is characterized by the development of new onset hypertension (HTN) and the establishment of proteinuria. Other signs and symptoms that accompany the disease include: headache, visual disturbances, epigastric or abdominal pain, weakness, altered mental status, HELLP syndrome (2) dyspnea and edema (American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy, 2013).

Previous preeclamptic pregnancy, family history of preeclampsia, late age of maternity (>40 years), multiple gestation, obesity, diabetes mellitus and history of thrombophilia have been identified as predisposing risk factors (American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy, 2013). In particular, the presence of HTN and chronic renal impairment before gestation has been strongly correlated to the development of preeclampsia later during pregnancy (Foo et al., 2015).

Preeclampsia can result in a great number of severe and, in some cases, fatal short- and long-term consequences affecting both the mother and the fetus. Maternal complications include cardiometabolic disorders (diabetes, ischemic heart disease, metabolic syndrome), cerebrovascular disease (stroke, intracranial bleeding), neurologic abnormalities (eclamptic seizures) and renal impairment (Ramsay et al., 2003; Wilson et al., 2003; Haukkamaa et al., 2004; Funai et al., 2005).

Fetal outcomes include intrauterine growth restriction (IUGR), prematurity and higher risk of developing HTN, obesity, metabolic syndrome, dyslipidemias, and cardiovascular disease (Lo et al., 2013; Nice guidelines, 2016).